Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pinaki Biswas

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Plos One|October 3, 2012
A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patientsRon M Kagan, Erik P Johnson, Martin Siaw, et al.
The Journal of Dermatological Treatment|June 28, 2022
Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of lifeAndrew Blauvelt, Mark Boguniewicz, Patrick M Brunner, et al.
Allergy|November 21, 2023
Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergiesPeter Schmid-Grendelmeier, Melinda J Gooderham, Karin Hartmann, et al.
Dermatology and Therapy|June 27, 2026
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc AnalysisStephen Weidinger, Kristian Reich, Naiem Issa, et al.
Dermatology and Therapy|August 6, 2022
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b TrialMelinda J Gooderham, Giampiero Girolomoni, Julian O Moore, et al.
BMC Infectious Diseases|February 25, 2014
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trialJose Vazquez, Annette C Reboli, Peter G Pappas, et al.
BMC Infectious Diseases|October 4, 2011
Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcomeAnnette C Reboli, Andrew F Shorr, Coleman Rotstein, et al.
JAMA Dermatology|June 4, 2020
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical TrialJonathan I Silverberg, Eric L Simpson, Jacob P Thyssen, et al.
Arthritis Research & Therapy|June 24, 2016
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritisMark C Genovese, Ronald F van Vollenhoven, Bethanie Wilkinson, et al.
Annals of Internal Medicine|July 16, 2008
Empirical fluconazole versus placebo for intensive care unit patients: a randomized trialMindy G Schuster, John E Edwards, Jack D Sobel, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Plos One|October 3, 2012
A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patientsRon M Kagan, Erik P Johnson, Martin Siaw, et al.
The Journal of Dermatological Treatment|June 28, 2022
Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of lifeAndrew Blauvelt, Mark Boguniewicz, Patrick M Brunner, et al.
Allergy|November 21, 2023
Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergiesPeter Schmid-Grendelmeier, Melinda J Gooderham, Karin Hartmann, et al.
Dermatology and Therapy|June 27, 2026
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc AnalysisStephen Weidinger, Kristian Reich, Naiem Issa, et al.
Dermatology and Therapy|August 6, 2022
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b TrialMelinda J Gooderham, Giampiero Girolomoni, Julian O Moore, et al.
BMC Infectious Diseases|February 25, 2014
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trialJose Vazquez, Annette C Reboli, Peter G Pappas, et al.
BMC Infectious Diseases|October 4, 2011
Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcomeAnnette C Reboli, Andrew F Shorr, Coleman Rotstein, et al.
JAMA Dermatology|June 4, 2020
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical TrialJonathan I Silverberg, Eric L Simpson, Jacob P Thyssen, et al.
Arthritis Research & Therapy|June 24, 2016
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritisMark C Genovese, Ronald F van Vollenhoven, Bethanie Wilkinson, et al.
Annals of Internal Medicine|July 16, 2008
Empirical fluconazole versus placebo for intensive care unit patients: a randomized trialMindy G Schuster, John E Edwards, Jack D Sobel, et al.
Pageof 6